Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nichi-Iko Pharmaceutical Co., Ltd.

http://www.nichiiko.co.jp/english

Latest From Nichi-Iko Pharmaceutical Co., Ltd.

Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments

Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.

Sales & Earnings Strategy

Lupin Liquidating Japan JV With Yoshindo, Partners With I’Rom For Denosumab Biosimilar

Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.

Strategy Deals

Lupin Liquidating Japan JV With Yoshindo, Partners I’Rom For Denosumab Biosimilar

Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.

Commercial Biosimilars

Sawai Urges Japan To Take 'Best And Only Chance' To Reform Pricing Amid Generic Crisis

Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, talks about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis in an exclusive interview. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.

Japan Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Elmed Eisai Co., Ltd
    • Nichi-Iko Medical Practice Institution Co., Ltd.
    • Yakuhan Pharmaceutical Co., Ltd.
    • Nichi-Iko Pharma Tech Co., Ltd.
    • Omega Laboratories Limited
    • Sagent Pharmaceuticals Inc.
    • Nihon Iyakuhin Kogyo Co., Ltd.
UsernamePublicRestriction

Register